Category Drug news

TRIMBOW® is the commercial brand name of Beclometasone Dipropionate, Formoterol Fumarate and Glycopyrrolate Inhalation Aerosol, a fixed-dose triple combination inhaled therapy containing inhaled corticosteroid, long-acting beta₂ agonist and long-acting muscarinic antagonist. It exerts anti-inflammatory and bronchodilatory effects to relieve airway…

Wakix® (Pitolisant Hydrochloride Tablets) is a selective histamine H3 receptor antagonist and inverse agonist. It enhances central histaminergic neurotransmission to promote wakefulness and regulate sleep-wake cycle. Main IndicationsTreatment of excessive daytime sleepiness in adult patients with narcolepsy, with or without…

Fampyra™ is the commercial brand name of Fampridine Sustained‑release Tablets, an oral potassium‑channel blocker developed by Biogen. It blocks voltage‑gated potassium channels on demyelinated nerve fibres, enhances nerve impulse conduction, thus improving motor function in multiple‑sclerosis patients. Main IndicationsImprovement of…

Trittico® is the commercial brand name of Trazodone Hydrochloride Sustained‑release Tablets, an oral serotonin‑modulating antidepressant developed by Angelini Pharma of Italy. It acts on multiple serotonin receptors in the central nervous system to regulate serotonin transmission and exert antidepressant, anxiolytic…

Seroxat® is the commercial brand name of Paroxetine Hydrochloride Enteric‑Coated Sustained‑Release Tablets, an oral selective serotonin reuptake inhibitor (SSRI) antidepressant developed by GSK. It inhibits presynaptic serotonin re‑uptake in the central nervous system and increases synaptic serotonin concentration to produce…

Invega Trinza® is the commercial brand name of Paliperidone Palmitate Injection (3M), a long‑acting injectable atypical antipsychotic developed by Janssen. It is the three‑month long‑acting depot ester prodrug of paliperidone, blocking dopamine D2 and serotonin 5‑HT2A receptors to exert antipsychotic…

Austedo® is the commercial brand name of Deutetrabenazine Tablets, an oral deuterated VMAT‑2 inhibitor developed by Teva Pharmaceuticals. It reversibly inhibits vesicular monoamine transporter 2, reducing presynaptic dopamine release to alleviate involuntary hyperkinetic movement disorders. Main IndicationsTreatment of chorea associated…

Lonasen® is the commercial brand name of Blonanserin Tablets, an oral atypical antipsychotic developed by Sumitomo Dainippon Pharma of Japan. It is a dual dopamine‑serotonin antagonist that blocks dopamine D2 and serotonin 5‑HT2A receptors, relieving both positive and negative psychotic…

Abilify Maintena® is the commercial brand name of Aripiprazole for Injection, a long-acting injectable atypical antipsychotic. It acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, delivering sustained therapeutic concentrations after intramuscular injection to stabilize psychiatric symptoms.…

Aliwei® is the commercial brand name of Ariprazole Microspheres for Injection, a long-acting injectable atypical antipsychotic. As a partial agonist of dopamine D2 and serotonin 5-HT1A receptors, it continuously regulates central neurotransmitter levels to control psychotic symptoms after intramuscular administration.…